Rare lephants
Screener

Taysha Gene Therapies, Inc.

TSHA ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Taysha Gene Therapies, Inc.

Total Moat Score 7 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Taysha's proprietary miRARE regulatory element and its stack of FDA designations (Fast Track, RMAT, Breakthrough Therapy) for TSHA-102 represent real, differentiated technology, though core IP is licensed in from several academic partners rather than wholly owned.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 As a pre-commercial clinical-stage company with no approved product or manufacturing scale, Taysha has no cost advantage over any competitor.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 0 / 5 With no approved product yet, Taysha has no current pricing power; any future pricing power is entirely contingent on REVEAL Part B results and regulatory approval.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 Gene therapy development for a rare neurodevelopmental disease has no network effect dynamic of any kind.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 A one-time administered gene therapy, if approved, would not involve an ongoing switching decision the way chronic medications do, giving this category limited relevance until TSHA-102 is actually approved.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 3 / 5 With a Rett syndrome addressable population of only about 6,000-9,000 U.S. patients, the market is small enough that a single approved, effective gene therapy could become the default standard of care, discouraging a second entrant from profitably competing.